RxDoctor Payments Data

Gregory Sachs, DO

Family Medicine · du Bois, PANPI 1063488781

Payments from drug & device makers

$6,161in general payments, 2019–2025

Across 405 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$540
  • Pfizer$486
  • Amgen$481
  • Gilead$291
  • Merck$243
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,12599%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,161 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,230
Medicare patients
373
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin183$166,161
EliquisApixaban241$153,366
OzempicSemaglutide99$106,773
TrulicityDulaglutide51$53,211
XareltoRivaroxaban92$43,414
JanuviaSitagliptin Phosphate35$30,467
RybelsusSemaglutide27$26,823
FarxigaDapagliflozin Propanediol30$25,823
OxycontinOxycodone Hcl18$21,256
TradjentaLinagliptin24$21,017
MounjaroTirzepatide18$18,367
MyrbetriqMirabegron46$14,785
Praluent PenAlirocumab24$11,284
Breo ElliptaFluticasone/Vilanterol27$11,270
NeuproRotigotine19$10,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$170$187,178207 claims
PfizerEliquis$486$153,366241 claims
Novo NordiskOzempic, Rybelsus$1,390$133,596126 claims
Lilly USA, LLCTrulicity, Mounjaro$169$71,57969 claims
Johnson & JohnsonXarelto$139$43,41492 claims
MerckJanuvia$243$30,46735 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$212$29,38955 claims
AstraZenecaFarxiga$210$25,82330 claims
Astellas Pharma US IncMyrbetriq$65$14,78546 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta$18$11,20424 claims
UCB, Inc.Neupro$20$10,12819 claims
AbbVieFetzima, Restasis$540$9,81725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →